Physician profile
Michael Shim
NPI 1851503353
$10,298.43
in general payments reported to CMS, 2019-2025
32 companies · $2,555 in 2025
The $2,555 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $219 · 2021: $857 · 2022: $1,542 · 2023: $1,781 · 2024: $1,929 · 2025: $2,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,264.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,527.63 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,150.32 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,036.51 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $586.86 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $551.15 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $476.82 | 2019-2025 | |
| Celgene Corporation | $411.82 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $299.26 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $265.10 | 2024-2025 | Omvoh |
| Genzyme Corporation | $257.51 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $245.35 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $241.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $216.33 | 2025 | Zymfentra, Vegzelma |
| Allergan, INC. | $214.10 | 2019 | |
| Merck Sharp & Dohme LLC | $147.76 | 2019-2024 | Dificid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $91.05 | 2019-2022 | |
| Braintree Laboratories, INC. | $74.98 | 2019-2025 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $61.11 | 2024-2025 | Voquezna |
| Amgen INC. | $58.03 | 2021 | |
| Ironwood Pharmaceuticals, INC | $53.32 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $50.03 | 2019 | |
| Ucb, INC. | $49.17 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $46.63 | 2025 | Iqirvo |
| Novo Nordisk INC | $43.46 | 2025 | Wegovy |
| Ardelyx, INC. | $25.22 | 2023 | Ibsrela |
| Intra-Sana Laboratories | $21.02 | 2021 | |
| Pinnacle Biologics, INC | $18.82 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.03 | 2021 | |
| Redhill Biopharma INC. | $16.66 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.34 | 2025 | Sutab |
| Alfasigma USA, INC. | $14.66 | 2020 | |
| Evoke Pharma, INC. | $14.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.